An Open-label Study in Healthy Male Subjects, to Determine the Excretion Balance and Pharmacokinetics of [14C]-GSK2269557, Administered as a Single Intravenous Microtracer (Concomitant With an Inhaled Non-radiolabelled Dose) and a Single Oral Dose
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Nemiralisib (Primary) ; Nemiralisib (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Immunodeficiency disorders
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 10 Jan 2018 Status changed from recruiting to completed.
- 27 Nov 2017 Status changed from not yet recruiting to recruiting.
- 13 Nov 2017 Planned End Date changed from 12 Dec 2017 to 22 Dec 2017.